The lysosomal storage disorder glycogenosis type II is caused by acid a-glucosidase deficiency. In this study we have investigated the possible applicability of mannose 6-phosphate receptor-mediated enzyme replacement therapy to correct the enzyme deficiency in the most affected tissues. Bovine testes acid a-glucosidase containing phosphorylated mannose residues was intravenously administered to mice and found to be taken up by heart (70% increase of activity) and skeletal muscle (43% increase); the major target organs. The uptake of nonphosphorylated human placenta acid a-glucosidase by heart and skeletal muscle appeared to be significantly less efficient, whereas uptake of dephosphorylated bovine testes enzyme was not detectable. The phosphorylated bovine testes acid a-glucosidase remained present in mouse skeletal muscle up to 9-15 d after administration, with a half-life of 2-4 d. Besides being measured in skeletal muscle and heart, uptake of phosphorylated bovine testes and nonphosphorylated human placenta acid aglucosidase was measured in several other organs, but not in brain. The increase ofacid a-glucosidase activity was highest in liver and spleen. We concluded that application of mannose 6-phosphate receptor-mediated enzyme replacement therapy may offer new perspectives for treatment of glycogenosis type II. (J. Clin. Invest. 1991. 87:513-518.)
Introduction
Glycogenosis type II is one of the more than 30 lysosomal storage disorders, and is caused by inherited deficiency of acid a-glucosidase (1, 2) . Patients with an early onset infantile form of this disease have little or no residual enzyme activity (3) (4) (5) (6) (7) (8) . They present shortly after birth with severe hypotonia and cardiorespiratory insufficiency. Their life expectancy is less than two years. In late onset variants skeletal muscle weakness is the major feature. The heart is mostly not affected. Respiratory failure is the major cause of death. In these juvenile and adult phenotypes, acid a-glucosidase activities up to -20% of normal have been reported (3) (4) (5) (6) (7) (8) .
In the early 1 970s much thought was given to the idea that lysosomal storage diseases could possibly be cured by enzyme Receivedfor publication 26 June 1989 and in revisedform 25 July 1990. replacement therapy (9) (10) (11) (12) (13) . This view gained interest when degradation of storage compounds was demonstrated after uptake of enzyme by cultured fibroblasts from patients with mucopolysaccharidoses (14-16). But the number of clinical trials remained small for the obvious reason that highly purified lysosomal enzymes were only available in very limited amounts. Moreover, infused enzyme was found to be captured predominantly by the liver and the spleen when administered to animals or to patients. Uptake of enzyme in other organs was hardly observed (9) (10) (11) (12) (13) (17) (18) (19) (20) . Attempts at enzyme replacement therapy for glycogenosis type II have failed (21) (22) (23) .
To circumvent these problems alternative approaches were taken to supply the lacking enzymes, for instance via cell or tissue transplantation (24) (25) (26) (27) , plasma transfusion (28) , and bone marrow transplantation (29) (30) (31) (32) . The last of these methods attracts, at present, most attention, and seems promising for treatment of those diseases in which storage material accumulates in macrophages. Encouraging results have been reported in Gaucher disease type 1 and Hurler disease, but the long-term beneficial effects of bone marrow transplantation as therapy for lysosomal storage disorders need further evaluation (29) (30) (31) (32) . There is, unfortunately, little reason to be optimistic about the curative effect of bone marrow transplantation in glycogenosis type II. The reported attempts at treatment of patients with the severe infantile form of this disease were unsuccessful, while application of bone marrow transplantation in adult glycogenosis type II is not advised considering the risks of the procedure (31, 33, 34) .
With this in mind we started to explore the feasibility of receptor-mediated enzyme replacement therapy for glycogenosis type II, using the 270-kD mannose 6-phosphate receptor, exposed on the cell surface of cardiomyocytes and skeletal muscle cells, as enzyme target. This receptor was first recognized for its function in endocytosis of mannose 6-phosphate containing lysosomal enzymes (35, 36) , but is presently known to be also involved in the intracellular transport of newly synthesized enzymes to lysosomes (37) . Another quite different function ofthis receptor is binding ofinsulin-like growth factor 11 (38) (39) (40) .
In previous studies we have shown that mannose 6-phosphate-containing acid a-glucosidases, isolated from human urine and bovine testes, are taken up efficiently by cultured muscle cells and fibroblasts from patients with glycogenosis type II. As a result, the excessive amount of lysosomal glycogen is degraded (7, 8, 41, 42) . In this study we have determined the fate of intravenously injected mannose 6-phosphate containing acid a-glucosidase in mice. methylumbelliferone (MU)1/mg/h), and a nonphosphorylated form of acid a-glucosidase from human placenta (sp act 392 MAmol MU/mg per h) (43, 44, 45) . The capacity of these enzymes to bind to mannose 6-phosphate receptors was tested as described before (7, 8, 41) . Uptake of bovine testes acid a-glucosidase by cultured human fibroblasts was found to be -160-fold more efficient than uptake of human placenta enzyme, and was 98% inhibited by 5 mM mannose 6-phosphate.
In a separate series ofexperiments purified bovine testes acid a-glucosidase was dephosphorylated by incubation for 16 h, at 370C, in 0.1 M ammoniumbicarbonate, pH 7.0, containing 75 U of immobilized alkaline phosphatase (Sigma Chemical Co., St. Louis, MO). As a control, a second lot of enzyme was incubated under identical conditions but without alkaline phosphatase. In both cases the catalytic activity was lost. The apparent molecular mass of the enzyme remained the same. The uptake ofphosphorylated and dephosphorylated enzyme by cultured fibroblasts was tested by immunoblotting as described below.
The different enzyme preparations were intravenously administered to 6-wk old Swiss mice (30 g) via the tail veins. After 24 h or longer periods the animals were anesthetized, and thoracotomy was performed (46) . A heparinized cannula connected to a perfusion apparatus was inserted in the left ventricle, and the right atrium was disrupted. The animals were perfused with 10 ml of a 0.1% procain-HCI solution in PBS, pH 7.2, at 370C. Brain, liver, spleen, kidneys, heart, lungs, and muscles (soleus, quadriceps, and pectoral muscles) were then quickly removed, frozen in liquid nitrogen, and stored at -700C.
Biochemical assays. Tissue specimens (0.1-0.2 g wet wt) were homogenized in 400 ,l ofdistilled water, using a Potter Elvejem homogenizer at 1,300 rpm and a sonicator (Measuring and Scientific Equipment, Loughborough, UK). Cell debris was removed by centrifugation at 15,000 g. The protein concentration of the samples was measured according to Lowry et al. (47) , and the acid a-glucosidase activities were determined as previously described, using 4-methylumbelliferyla-D-glucopyranoside as substrate (48). Enzyme activities are expressed in nanomoles MU liberated per hour. Immunoprecipitation. Antisera against bovine testes and human placenta acid a-glucosidase were raised in Swiss mice to discriminate between infused exogenous enzymes and mouse endogenous acid aglucosidase. These antisera precipitate 90-95% of bovine testes and human placenta acid a-glucosidase, but < 2% of the enzyme from mouse tissues (49) . Tissue homogenates from mice injected with acid a-glucosidase and from control animals injected with PBS (10 mM sodium phosphate and 0.9% NaCl), were diluted in PBS, pH 6.8, containing I mg/ml BSA to an acid a-glucosidase activity of I ;mol MU/h per 20 Ml. Purified enzyme preparations from bovine testes and human placenta were diluted in the same way. Samples of20 Ml were incubated overnight at 4°C with 10 ,ul of a 400-fold diluted antiserum in PBS/ BSA or with PBS/BSA alone. Staphylococcus A membranes (10 ul; Bethesda Research Laboratories, Gaithersburg, MD) were added to precipitate immune complexes. The membranes were spun down at 15,000 g, and the acid a-glucosidase activity was measured in the supernatant, and on the membranes after six washes with PBS/BSA.
Immunoblotting. Tissue homogenates from control mice, and mice injected with bovine testes acid a-glucosidase were incubated with a mouse antiserum raised against this enzyme. Immune complexes were precipitated with protein A Sepharose beads (50 ,ul of a 1:1 suspension in PBS) at 4°C. The beads were washed f6ur times with PBS, and bound complexes were dissolved by heating for 10 min at 90°C in sample buffer (125 mM Tris-HCl, pH 6.6, 2 M glycerol, 4% SDS, 0.6% mercaptoethanol, and 0.05% bromophenol blue). Samples were subsequently subjected to electrophoresis in 10% polyacrylamide gels and blotted onto nitrocellulose (50, 51) . Bovine testes acid a-glucosidase was visualized with mouse antiserum specifically raised against this enzyme, using '25N-labeled protein A as radioactive probe (51) . In an alternative procedure the immune complexes were visualized with goat 1. Abbreviation used in this paper: MU, methylumbelliferone.
antibodies against mouse IgG conjugated to alkaline phosphatase (Tago, Inc., Burlingame, CA).
Results
In a pilot experiment, two 6-wk old mice (weight, 30 g) were injected with 90 and 180 Ag (equivalent to 32 and 64 ,umol MU/h) of mannose 6-phosphate containing bovine testes acid a-glucosidase. After 24 h the mice were killed and the activity of bovine testes acid a-glucosidase in the mouse organs was measured by means of species-specific enzyme immunoprecipitation. (The antiserum used for this purpose precipitates 90-95% ofbovine testes acid a-glucosidase, but < 2% ofthe endogenous mouse enzyme.) Table I shows the percentage ofprecipitable acid a-glucosidase activity in mouse tissues after enzyme administration, as well as the increase of enzyme activity per tissue. Brain did not contain a measurable amount of infused enzyme, but in all other tissues a dose-dependent uptake of bovine testes acid a-glucosidase was observed. The effect of enzyme infusion was most pronounced in liver and spleen, but was also noted in muscle, heart, lung, and kidney.
The molecular mass ofthe immunoprecipitated acid a-glucosidase was determined to further define the origin of the enzyme activity in the mouse tissues. To this end, the enzyme precipitated from muscle and liver was subjected to polyacrylamide gel electrophoresis in the presence of SDS and analyzed by immunoblotting. The results are presented in Fig. 1 . The precipitated enzyme had the same molecular mass (70 kD) as the administered bovine testes acid a-glucosidase, and this enzyme species was only detectable in mouse tissues after enzyme infusion (lanes 2 and 4) . The cross-reactive proteins of higher relative molecular weight (lanes 2 and 3) are of mouse origin.
In a following experiment the stability of endocytosed enzyme was studied. For this purpose 13 mice were injected with 180 ,Ag of purified bovine testes acid a-glucosidase. The enzyme remained detectable in serum until 1 h after injection. The animals were killed on day 1, 3, 6, 9, and 15 after enzyme infusion, and the increase of acid a-glucosidase activity in the various tissues was determined as described above via immunoprecipitation of bovine testes acid a-glucosidase (Table II) Table II (day 1). It appeared that the human placenta and the bovine testes enzymes were taken up with about the same efficiency by liver, spleen, and lungs. However, administration of mannose 6-phosphate containing bovine testes acid a-glucosidase led to a two to three times higher uptake in heart and skeletal muscle than infusion of the same amount of enzyme isolated from human placenta. 8±3.6 (n = 2) * The increase is expressed as percentage of the tissue-specific endogenous activity. 180 sg of acid a-glucosidase from bovine testes (b.t.) or human placenta (h.pl.) was injected. n, number of mice (two animals were tested on day 3, 6, and 15, and one on day 9); x, number of muscles analyzed including quadriceps, soleus, and pectoral muscles.
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To exclude the possibility that the differences in the fates of the human placenta and the bovine testes acid a-glucosidase were due to factors other than the mannose 6-phosphate content of the sugar chains the following experiment was conducted. Bovine testes acid a-glucosidase was dephosphorylated by incubation with alkaline phosphatase. The effect of this treatment was assayed by comparing the uptake efficiency of phosphorylated and dephosphorylated enzyme by cultured fibroblasts from a patient with a complete enzyme deficiency. Immunoblot analysis revealed that alkaline phosphatase treatment abolished the uptake of bovine testes acid a-glucosidase by fibroblasts completely. The condition of alkaline phosphatase treatment per se did not affect the efficiency of enzyme uptake. Six mice were injected with dephosphorylated enzyme, six with phosphorylated enzyme, and a third group with PBS. Of each group, three animals were killed 1 d after infusion and three on day 3. Homogenates were made ofthe quadriceps and pectoral muscles and bovine testes acid a-glucosidase was immunoprecipitated, as described above. Polyacrylamide gel electrophoresis followed by immunoblotting was performed to analyze these samples for the presence of bovine testes enzyme. The results obtained are shown in Fig. 2 A (pectoral muscle) and Fig. 2 B (quadriceps muscle) . The 70-kD bovine testes acid a-glucosidase is only detectable in skeletal muscle tissue after injection of mannose 6-phosphate containing enzyme (lanes 3 and 6).
One of the animals infused with bovine testes acid a-gluco- 
Discussion
This study was conducted to investigate the feasibility of mannose 6-phosphate receptor-mediated enzyme replacement therapy for glycogenosis type II. Mannose 6-phosphate containing acid a-glucosidase isolated from bovine testes is shown to be taken up by the major target organs after intravenous injection. A 43% increase ofacid a-glucosidase activity in skeletal muscle and a 70% increase in heart was measured, notably higher than obtained with a similar dose (180 Mg) of nonphosphorylated acid a-glucosidase purified from human placenta. Uptake of bovine testes a-glucosidase becomes undetectable after dephosphorylation. These results suggest that the mannose 6-phosphate receptor facilitates enzyme uptake in skeletal muscle and cardiac tissue. Also in a recent series of experiments in which isolated rat hearts were perfused with different forms of acid a-glucosidase we were able to demonstrate a more efficient uptake of mannose 6-phosphate containing enzyme (52) . The way of transport of lysosomal enzymes from the plasma to the target cells remains of interest. Suggestive evidence was recently obtained that plasmalemmal vesicles are involved (53) .
The major fraction of infused enzyme is captured by the liver and the spleen, with little distinction between phosphorylated and nonphosphorylated enzyme species. It is likely that most activity in these tissues resides in macrophages known to express both the mannose and the mannose 6-phosphate receptors (54) . Brain remains completely devoid of exogenous enzyme activity which is obviously due to the blood brain barrier (55, 56) . Thus, our results are in general agreement with earlier observations on the fate of infused enzymes in clinical trials and in animal models (17-20, 57, 58) . Passage across the placental barrier separating the maternal and fetal circulation is apparently not possible either, since infused enzyme was only recovered in maternal and not in fetal tissues.
To evaluate the practical significance of our study for enzyme replacement therapy in glycogenosis type II, the following considerations are important. Most patients with late onset glycogenosis type II have a residual acid a-glucosidase activity between 10 and 20% of the average control value (3) (4) (5) (6) (7) (8) . This suggests that lysosomal glycogen storage does not occur when the residual enzyme activity is more than -20%. Model experiments with cultured muscle cells support this assumption (7, 8) . Therefore, a slight increase ofacid a-glucosidase activity might be sufficient to prevent or reverse lysosomal glycogen storage and clinical symptoms.
In this study a 43% increase of activity is measured in mouse skeletal muscle one day after enzyme administration. Six days later the level ofactivity is still 10-20% above normal, which would in principle be sufficient to compensate the enzyme deficiency in adult glycogenosis type II. Our experiments therefore indicate that application ofenzyme replacement ther-
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Van der Ploeg, Kroos, Willemsen, Brons, and Reuser apy might be successful. But it is evident that efficient procedures have to be developed for large scale production ofhuman mannose 6-phosphate containing acid a-glucosidase before it can come to application of enzyme replacement therapy in clinical trials. The mice used in our studies received 90-180 Ag of purified enzyme. Calculated by body weight, 200-400 mg would be the equivalent amount of enzyme needed to obtain the same effect in humans. This is far more than the amount of acid a-glucosidase administered in the past to patients with infantile. glycogenosis type II. Moreover, the enzyme used in these early clinical trials had been purified from human placenta and therefore did not contain the mannose 6-phosphate recognition marker essential for efficient uptake in heart and skeletal muscle. This explains in retrospect why no curative effect was obtained.
When the estimated half-life ofbovine testes acid a-glucosidase in mouse tissues is representative for the half-life of human enzyme taken up by human tissues this would mean that an infusion of 200-400 mg of enzyme is required once every week for treatment of adult glycogenosis type II. Isolation of this amount of enzyme from human tissues is not within technical reach, but production of a sufficient amount of enzyme may become possible by using cloned human acid a-glucosidase cDNA (59) . We are presently exploring the feasibility of such an approach. In view of our findings and the predictable technological developments we think that the original idea of enzyme replacement therapy for treatment of lysosomal storage diseases deserves new attention.
While this paper was in preparation Barton et al. reported on the clinical improvement of a patient with Gaucher disease type I after long-term treatment with glucocerebrosidase (60) .
